Why Glioblastoma Can Return After Treatment

Why Glioblastoma Can Return After Treatment

Title history
  • Why Glioblastoma Can Return After Treatment — observed on 20261107-0409 UTC (YouTube)
🎙 Joe Costello, Ph.D. 👥 1.4M 📅 November 7, 2026 ⏱ 57 min 👁 37 📄 original study 🧭 2026-11-07
Available in: English (current) Français

Keywords

glioblastomatumor evolutionTERTrecurrenceclonal heterogeneity

Summary

Joe Costello presents his laboratory’s research on why glioblastoma often returns after treatment. He describes the use of 3D whole-tumor sampling, taking multiple spatially mapped samples across the tumor, to study tumor evolution. Findings reveal that many genetic alterations are homogeneous across the tumor, suggesting an early ancestral clone, which they term the ‘primogenitor,’ that predates the founder clone. This primogenitor clone survives therapy and gives rise to recurrence, resetting heterogeneity. The talk also covers cancer cell immortality via TERT activation, showing that most solid cancers activate TERT to maintain telomeres. Costello discusses targeting GABP, a transcription factor that activates TERT, using protein degraders and AI to identify targets. Preliminary results indicate that reducing TERT expression in cell lines and animal models improves survival. The research is early but offers new insights into glioblastoma resistance and potential therapeutic directions.

139 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation is rich in original data, including detailed phylogenetic analyses and copy number assessments. The argumentation is logically structured: from defining the problem of recurrence to presenting evidence for the primogenitor clone, then linking it to TERT-mediated immortality. Costello appropriately acknowledges limitations, such as the possibility of missing low-abundance clones and the need for further validation. He clearly distinguishes between established findings and hypotheses, supporting each with specific examples and quantitative data.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high; the talk is based on peer-reviewed publications (e.g., the 2024 Cell paper) and extensive unpublished data. Sources cited include UCTV repository links and the speaker’s own research. The title accurately captures the core question, and the content stays on topic. No promotional or unsubstantiated claims are made; the preliminary nature of the findings is consistently emphasized.

149 words

Title / Content Match

Title accurately reflects the content, focusing on tumor evolution and TERT-mediated immortality as mechanisms of recurrence.

Quality & Reliability

9/10

The talk is given by a leading researcher presenting original, unpublished data from peer-reviewed studies, with detailed methodological explanations and evidence from multiple assays. The information is current and relevant, though much remains preliminary.

Chapters

Cited Sources

Concurring Sources

External References

Contribution & Novelties

The talk presents a novel concept of ‘primogenitor’ clones that precede the founder clone and are the sole survivors of therapy, leading to recurrence. This challenges previous assumptions about the origin of recurrent tumors. Additionally, the integration of 3D sampling with genomic, epigenomic, and transcriptomic data provides a more comprehensive view of glioblastoma heterogeneity. The research also highlights potential therapeutic targets such as GABP, with promising preliminary results in experimental models.

Pour aller plus loin :

107 words

Radar Profile

The profile shows high scores in information quantity and quality, with a slightly lower technical level, indicating a detailed but accessible presentation. The overall reliability is strong, reflecting the speaker's expertise and the inclusion of original data.

Reliability 9/10